NUTX vs ASTH
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
NUTX · Nutex Health$180.56 ▼ 6.75%
ASTH · Astrana Health$34.50 ▼ 11.56%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- NUTX +51.9%
- ASTH +53.8%
Head to head
| Metric | NUTX | ASTH |
|---|---|---|
| Price | $180.56 | $34.50 |
| Change today | ▼ 6.75% | ▼ 11.56% |
| Market cap | $1.24B | $1.70B |
| Return, 3 months | -8.6% | -7.9% |
| Return, year to date | +9.7% | +39.1% |
| Return, 1 year | +57.5% | +35.1% |
| P/E (TTM) | 7.8 | 31.9 |
| P/B | 2.8 | 2.0 |
| P/E percentile vs own 5y | 68th | 73rd |
| Dividend yield | – | – |
| Revenue growth (YoY, latest qtr) | -13.6% | +48.5% |
| Net profit growth (YoY) | +496.6% | +80.6% |
| Gross margin | 51.3% | 10.5% |
| Operating margin | 43.0% | 2.6% |
| Net margin | 21.2% | 1.1% |
| Return on equity | 57.2% | 5.1% |
| Analyst target vs. price | +63.6% | +51.9% |
| Analyst buy share | 100% | 88% |
| RSI (14) | 41 | 40 |
| 30-day volatility | 67.7% | 53.8% |
| Max drawdown, 1 year | -54.3% | -46.4% |
| Trend read | Leaning bearish | Leaning bearish |
| Analyst consensus | Buy | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- ASTH is the largest of the group by market value.
- NUTX has returned the most over the past year.
- NUTX carries the lowest trailing P/E.
- ASTH is growing revenue fastest.
- NUTX keeps the most profit per dollar of sales.
- ASTH has been the calmest stock over the last 30 days.